STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 96 filers reported holding STOKE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46,949 | -90.7% | 11,916 | -74.8% | 0.00% | – |
| Q2 2023 | $502,491 | +33.6% | 47,271 | +4.7% | 0.00% | – |
| Q1 2023 | $376,116 | -8.3% | 45,152 | 0.0% | 0.00% | – |
| Q4 2022 | $409,997 | -30.1% | 45,152 | -0.1% | 0.00% | – |
| Q3 2022 | $586,576 | -2.6% | 45,185 | -0.8% | 0.00% | – |
| Q2 2022 | $602,505 | -20.2% | 45,529 | +32.0% | 0.00% | – |
| Q1 2022 | $755,349 | +188.3% | 34,499 | +216.5% | 0.00% | – |
| Q4 2021 | $262,000 | -3.7% | 10,901 | +2.0% | 0.00% | – |
| Q3 2021 | $272,000 | -29.4% | 10,683 | -6.6% | 0.00% | – |
| Q2 2021 | $385,000 | +21.1% | 11,440 | +39.6% | 0.00% | – |
| Q1 2021 | $318,000 | -35.0% | 8,196 | +3.8% | 0.00% | – |
| Q4 2020 | $489,000 | +91.8% | 7,896 | +3.6% | 0.00% | – |
| Q3 2020 | $255,000 | +4.9% | 7,620 | -28.1% | 0.00% | – |
| Q1 2020 | $243,000 | – | 10,603 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 17,161,713 | $666,561,000 | 74.20% |
| RTW INVESTMENTS, LP | 3,644,248 | $141,543,000 | 2.21% |
| Redmile Group, LLC | 2,544,062 | $98,811,000 | 1.39% |
| Cormorant Asset Management, LP | 1,437,807 | $55,844,000 | 1.24% |
| ACUTA CAPITAL PARTNERS, LLC | 45,000 | $1,748,000 | 0.63% |
| SPHERA FUNDS MANAGEMENT LTD. | 150,729 | $5,854,000 | 0.45% |
| HighVista Strategies LLC | 13,692 | $532,000 | 0.40% |
| Birchview Capital, LP | 15,000 | $583,000 | 0.35% |
| Perceptive Advisors | 671,978 | $26,100,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,265,950 | $49,169,000 | 0.26% |